Ixazomib (NINLARO®) capsules ( DrugBank: Ixazomib )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03783416 (ClinicalTrials.gov) | June 1, 2019 | 10/12/2018 | SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis | Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis: A Phase 1b Randomised, Double-blind, Placebo-controlled Trial. | Relapsing Remitting Multiple Sclerosis;Primary Progressive Multiple Sclerosis;Secondary Progressive Multiple Sclerosis | Drug: Ixazomib (NINLARO®) capsules / Matching placebo capsules | Queen Mary University of London | Takeda Pharmaceuticals International, Inc. | Not yet recruiting | 18 Years | 65 Years | All | 72 | Phase 1 | United Kingdom |